News >

Adjuvant T-DM1 Improves iDFS in Phase III HER2+ Breast Cancer Trial

Gina Columbus @ginacolumbusonc
Published: Monday, Oct 15, 2018

Dr. Sandra Horning
Sandra Horning, MD
Ado-trastuzumab emtansine (T-DM1; Kadcyla) was found to significantly reduce the risk of invasive disease recurrence or death compared with trastuzumab (Herceptin) as an adjuvant treatment in patients with HER2-positive early breast cancer who have residual disease following neoadjuvant therapy, according to topline findings of the phase III KATHERINE study.

Moreover, 136 of 496 patients crossed over from the lapatinib/capecitabine arm to T-DM1 after the second interim OS analysis.

References

  1. Verma S, Miles D, Gianni L. Updated overall survival results from EMILIA, a phase 3 study of T-DM1 (T-DM1) vs capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC). Paper presented at: 37th European Society for Medical Oncology Congress; September 28-October 2, 2012; Vienna, Austria. Abstract LBA12.
  2. Diéras V, Miles D, Verma S, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(6):732-742. doi: 10.1016/S1470-2045(17)30312-1.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x